Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
July 7, 1998
Assignee:
IDEC Pharmaceuticals Corporation
Inventors:
Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
Abstract: Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
May 26, 1998
Assignee:
IDEC Pharmaceuticals Corporation
Inventors:
Roland A. Newman, Nabil Hanna, Ronald W. Raab
Abstract: Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
May 12, 1998
Assignee:
IDEC Pharmaceuticals Corporation
Inventors:
Roland A. Newman, Nabil Hanna, Ronald W. Raab
Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Type:
Grant
Filed:
November 3, 1993
Date of Patent:
April 7, 1998
Assignee:
Idec Pharmaceuticals Corporation
Inventors:
Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
Abstract: Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector. These vectors are most typically utilized in the expression of proteins in mammalian expression systems. As defined, disclosed and claimed herein, a "fully impaired consensus Kozak" comprises the following sequence: ##STR1## where: "x" is a nucleotide selected from the group consisting of adenine (A), quanine (G), cytosine (C) or thymine (T)/uracil (U); "Py" is a pyrimidine nucleotide, ie C or T/U; "ATG" is a codon encoding for the amino acid methionine, the so-called "start" codon; and -3 and +1 are directional reference points vis-a-vis ATG, ie -3 is meant to indicate three nucleotides upstream of ATG and +1 is meant to indicate one nucleotide downstream of ATG. Dominant selectable markers further comprising artificial intronic insertion regions are further disclosed.
Abstract: Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.
Type:
Grant
Filed:
December 7, 1994
Date of Patent:
January 20, 1998
Assignee:
IDEC Pharmaceuticals Corporation
Inventors:
Syamal Raychaudhuri, William H. Rastetter
Abstract: Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
December 9, 1997
Assignee:
IDEC Pharmaceuticals Corporation
Inventors:
Syamal Raychaudhuri, William H. Rastetter, Amelia Black
Abstract: Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
December 2, 1997
Assignee:
Idec Pharmaceuticals Corporation
Inventors:
Roland A. Newman, Nabil Hanna, Ronald W. Raab
Abstract: Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
October 28, 1997
Assignee:
IDEC Pharmaceuticals Corporation
Inventors:
Roland A. Newman, Nabil Hanna, Ronald W. Raab
Abstract: Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use.
Type:
Grant
Filed:
January 25, 1995
Date of Patent:
August 19, 1997
Assignee:
Idec Pharmaceuticals Corporation
Inventors:
Roland A. Newman, Nabil Hanna, Ronald W. Raab
Abstract: Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector. These vectors are most typically utilized in the expression of proteins in mammalian expression systems. As defined, disclosed and claimed herein, a "fully impaired consensus Kozak" comprises the following sequence: ##STR1## where: Nat nucleotides 2,3,8 and 9 is a nucleotide selected from the group consisting of adenme (A), quanine (G), cytosine (C) or thymine (T)/uracil (U); Nat nucleotides 1 and 7 is a pyrimidine nucleotide, ie C or T/U; "ATG" is a codon encoding for the amino acid methionine, the so-called "start" codon; and -3 and +1 are directional reference points vis-a-vis ATG, ie -3 is meant to indicate three nucleotides upstream of ATG and +1 is meant to indicate one nucleotide downstream of ATG. Dominant selectable markers further comprising artificial intronic insertion regions are further disclosed.
Abstract: Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.
Type:
Grant
Filed:
July 24, 1992
Date of Patent:
December 17, 1996
Assignee:
IDEC Pharmaceutical Corporation
Inventors:
Syamal Raychaudhuri, William H. Rastetter